Ansbert Gadicke
CIK 1134655 · last filed 2025-11-03
Ansbert Gadicke is a corporate insider who has filed 84 SEC Form 4 insider transactions across 22 companies since 2007. The most recent filing shows the insider sold $391.6K of HOWL on Nov 3, 2025. Across all open-market trades the lifetime net is −$21.0M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $410.8M across reported positions. 164 SEC filings were submitted jointly with Luke Evnin.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
RPTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SUITE 1100
BOSTON, MA 02116
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| HOWL | 10%+ Owner | 6,355,717 | $1.01 | $6.45M | $3.08M | 3 | 2025-11-03 |
| TRDA | 10%+ Owner | 4,381,062 | $4.76 | $20.88M | -$917.1K | 1 | 2024-12-12 |
| TCR2 THERAPEUTICS INC. (TCRR) Delisted | Director | 374,171 | $1.48 | $553.8K | $20.47M | 2 | 2023-05-24 |
| Kalaris Therapeutics, Inc. (ALVR) Delisted | Director | 726,303 | $9.81 | $7.13M | $0 | 5 | 2022-08-01 |
| CGEM | Director | 7,892,819 | $12.05 | $95.10M | -$2.55M | 11 | 2022-06-23 |
| iTeos Therapeutics, Inc. (ITOS) Delisted | Director | 5,397,803 | $10.15 | $54.79M | -$8.04M | 6 | 2021-09-30 |
| Repare Therapeutics Inc. (RPTX) Delisted | 10%+ Owner | 3,940,497 | $2.65 | $10.44M | -$35.72M | 14 | 2021-07-13 |
| Harpoon Therapeutics, Inc. (HARP) Delisted | 10%+ Owner | 656,146 | $23.01 | $15.10M | -$2.25M | 3 | 2021-05-04 |
| Oncorus, Inc. (ONCR) Delisted | 10%+ Owner | 2,225,801 | $0.12 | $268.3K | $4.88M | 1 | 2020-10-08 |
| Radius Health, Inc. (RDUS) Delisted | Director | 3,887,502 | $30.00 | $116.63M | $0 | 7 | 2017-02-22 |
| CHIASMA, INC (CHMA) Delisted | Director | 2,498,597 | $3.76 | $9.39M | $0 | 2 | 2016-06-13 |
| ARATANA THERAPEUTICS, INC. (PETX) Delisted | 10%+ Owner | 37,117 | — | — | -$538.5K | 1 | 2014-03-11 |
| Epizyme, Inc. (EPZM) Delisted | 10%+ Owner | 2,880,485 | $1.47 | $4.23M | $0 | 1 | 2013-06-06 |
| PCRX | 10%+ Owner | 2,790,479 | $36.46 | $101.74M | -$7.18M | 3 | 2013-03-13 |
| VSTM | Director | 161,111 | $8.77 | $1.41M | $1.00M | 2 | 2012-03-08 |
| Pharmasset Inc (VRUS) Delisted | Director | 7 | — | — | $1.82M | 5 | 2008-06-18 |
| Altimmune, Inc. (PIP) Delisted | 10%+ Owner | 336,444 | — | — | $962.5K | 3 | 2007-10-29 |
| MEMY | 10%+ Owner | 14,238,773 | $13.01 | $185.25M | $0 | 2 | 2007-10-02 |
| Pernix Sleep, Inc. (SOMX) Delisted | 10%+ Owner | 429,084 | — | — | -$1.72M | 2 | 2007-05-03 |
| PONIARD PHARMACEUTICALS, INC. (PARDD) Delisted | 10%+ Owner | 6,858,211 | — | — | $5.70M | 1 | 2007-05-01 |
| CORNERSTONE THERAPEUTICS INC (CRTX) Delisted | 3,847,080 | $1.95 | $7.50M | $0 | 1 | 2007-02-15 | |
| COTHERIX INC (CTRX) Delisted | 10%+ Owner | 0 | — | — | $0 | 1 | 2007-01-10 |
Recent Filings
84 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2025-11-03 | HOWL | Sell (S) | −295,043 | -$391.6K | EDGAR |
| 2025-10-29 | HOWL | Sell (S) | −276,017 | -$446.4K | EDGAR |
| 2024-12-12 | TRDA | Sell (S) | −44,722 | -$917.1K | EDGAR |
| 2023-06-05 | — | Other (J) | −7,529,946 | $0 | |
| 2023-05-24 | TCR2 THERAPEUTICS INC. (TCRR) Delisted | Mixed | +108,099 | -$1 | EDGAR |
| 2022-08-01 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | +3,253,796 | $15.00M | EDGAR |
| 2022-06-23 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2022-05-19 | Kalaris Therapeutics, Inc. (ALVR) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-03-25 | CGEM | Grant (A) | — | $0 | EDGAR |
| 2021-09-30 | iTeos Therapeutics, Inc. (ITOS) Delisted | Sell (S) | −35,990 | -$971.7K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.